Bolt Biotherapeutics (BOLT) FCF Margin (2020 - 2025)
Historic FCF Margin for Bolt Biotherapeutics (BOLT) over the last 6 years, with Q3 2025 value amounting to 452.01%.
- Bolt Biotherapeutics' FCF Margin rose 7723600.0% to 452.01% in Q3 2025 from the same period last year, while for Sep 2025 it was 908.49%, marking a year-over-year decrease of 2829500.0%. This contributed to the annual value of 797.53% for FY2024, which is 878300.0% up from last year.
- As of Q3 2025, Bolt Biotherapeutics' FCF Margin stood at 452.01%, which was up 7723600.0% from 531.98% recorded in Q2 2025.
- Bolt Biotherapeutics' FCF Margin's 5-year high stood at 317.61% during Q1 2024, with a 5-year trough of 3613.39% in Q4 2021.
- Its 5-year average for FCF Margin is 1335.17%, with a median of 1159.03% in 2024.
- Per our database at Business Quant, Bolt Biotherapeutics' FCF Margin skyrocketed by 23280600bps in 2022 and then crashed by -7760800bps in 2025.
- Quarter analysis of 5 years shows Bolt Biotherapeutics' FCF Margin stood at 3613.39% in 2021, then skyrocketed by 64bps to 1285.33% in 2022, then skyrocketed by 47bps to 683.15% in 2023, then crashed by -79bps to 1224.36% in 2024, then soared by 63bps to 452.01% in 2025.
- Its last three reported values are 452.01% in Q3 2025, 531.98% for Q2 2025, and 1093.7% during Q1 2025.